Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.
Plasma and cervicovaginal secretion (CVS) samples were collected from 19 human immunodeficiency virus type 1-infected women on lopinavir- or indinavir-containing regimens. Lopinavir and indinavir were detectable in 29 and 93% of CVS samples, respectively, a finding that may be ascribed to these drugs' differences in protein binding and pK(a). The relationship between lopinavir and indinavir pharmacodynamics and viral evolution in the female genital tract should be assessed over time.
Launay
Odile
O
Fédération de Médecine Interne, Maladies Infectieuses et Tropicales and UPRES EA 3409, Université Paris-Nord, Bobigny, France. odile.launay@cch.ap-hop-paris.fr
Tod
Michel
M
Louchahi
Kamel
K
Belarbi
Linda
L
Bouchaud
Olivier
O
Mémain
Nathalie
N
Petitjean
Olivier
O
Robineau
Michel
M
Guillevin
Loïc
L
Lortholary
Olivier
O
D000328:Adult; D019380:Anti-HIV Agents / Q000097:blood / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D005260:Female; D005836:Genitalia, Female / Q000378:metabolism*; D015658:HIV Infections / Q000378:metabolism*; D015497:HIV-1; D006801:Humans; D019469:Indinavir / Q000097:blood / Q000493:pharmacokinetics*; D061466:Lopinavir; D011485:Protein Binding; D011744:Pyrimidinones / Q000097:blood / Q000493:pharmacokinetics*; D014621:Vagina / Q000378:metabolism
D019380:Anti-HIV Agents; D011744:Pyrimidinones; D061466:Lopinavir; D019469:Indinavir